Supplementary Figure legends

Supplementary Figure S1. Odds ratios for prostate cancer associated with an 80 percentile increase in IGF-II among all cases and their matched controls

Supplementary Figure S2. Odds ratios for prostate cancer associated with an 80 percentile increase in IGFBP-1 among all cases and their matched controls (data are only available for IGFBP-1 from prospective studies and not cross-sectional studies)

Supplementary Figure S3. Odds ratios for prostate cancer associated with an 80 percentile increase in IGFBP-2 among all cases and their matched controls

Supplementary Figure S4. Odds ratios for prostate cancer associated with an 80 percentile increase in IGFBP-3 among all cases and their matched controls

Supplementary Figure S5. Odds ratios for prostate cancer associated with an 80 percentile increase in IGF-I among all cases and their matched controls in all studies, subdivided by various factors

Supplementary Figure S6. Odds ratios for prostate cancer associated with an 80 percentile increase in IGF-II among all cases and their matched controls, subdivided by various factors

Supplementary Figure S7. Odds ratios for prostate cancer associated with an 80 percentile increase in IGF-II among cases and their matched controls in prospective studies, subdivided by various factors

Supplementary Figure S8. Odds ratios for prostate cancer associated with an 80 percentile increase in IGFBP-1 among cases and their matched controls in prospective studies, subdivided by various factors (data are only available for IGFBP-1 from prospective studies and not cross-sectional studies)

Supplementary Figure S9. Odds ratios for prostate cancer associated with an 80 percentile increase in IGFBP-2 among all cases and their matched controls, subdivided by various factors

Supplementary Figure S10. Odds ratios for prostate cancer associated with an 80 percentile increase in IGFBP-2 among cases and their matched controls in prospective studies, subdivided by various factors

Supplementary Figure S11. Odds ratios for prostate cancer associated with an 80 percentile increase in IGFBP-3 among all cases and their matched controls, subdivided by various factors
Supplementary Figure S12. Odds ratios for prostate cancer associated with an 80 percentile increase in IGFBP-3 among cases and their matched controls in prospective studies, subdivided by various factors.

Supplementary Figure S13. Odds ratios for aggressive prostate cancer by study-specific fifths of concentrations of selected insulin-like growth factors and their binding proteins among cases and their matched controls in prospective studies.

Supplementary Figure S14. Odds ratios for prostate cancer by study-specific fifth of selected IGFs in cases and their matched controls in all studies, adjusted for marital status, educational level, smoking status and BMI.

Supplementary Figure S15. Odds ratios for prostate cancer by study-specific fifth of selected IGFs in cases and their matched controls in prospective studies, adjusted for marital status, educational level, smoking status and BMI.